Talk to an expert

Tell us what you need and we will call you back.

🇮🇳 +91

    Stock audit glossary · Pharmaceuticals

    Active Pharmaceutical Ingredient (API)

    noun · abbreviated API; often called the active ingredient or bulk drug

    Definition

    An active pharmaceutical ingredient (API) is the substance in a medicine that produces its intended therapeutic effect. The other materials in the dose, the excipients, carry, bind, preserve or flavour it. In a pharmaceutical store the API is usually the costliest input and the most tightly controlled, and it is tracked batch by batch from receipt to the finished product it went into.

    • Reviewed by CA Sundram Gupta · Chartered Accountant
    • Last reviewed 23 October 2026
    • 7 min read

    See related terms

    At a glance

    Is
    The part of a medicine that acts Excipients carry it
    Usually
    The costliest input in a batch By value, not by weight
    Tracked by
    Batch number From receipt to finished product
    Counted with
    Its release status Quarantined, released or due for retest
    Made under
    A state manufacturing licence And Schedule M good manufacturing practice

    Meaning

    01 What an active pharmaceutical ingredient is

    Only a small part of a tablet or vial does the therapeutic work. The rest of the mass gives the dose its shape, stability and taste. That small active part usually carries most of the material cost of a batch and nearly all of the regulatory attention, so it is bought against a specification, stored in set conditions and issued only against a batch record.

    For a stock count this changes what “present” means. A drum of API on the rack can be used only once quality control has released it and while its retest date has not passed. Material still awaiting a quality decision, or overdue for retest, looks exactly like released stock, so the count records batch and release status next to the weight.

    Who holds it

    02 Which businesses hold API stock, and why it matters

    The same drum means different things to different holders.

    Who holds it

    • Formulation manufacturers. The API is their most valuable input and the tightest-controlled line in the store.
    • Bulk drug makers. For them the API is the finished product, ready for sale to formulators.
    • Contract manufacturers, distributors and importers. They often hold material that belongs to a client, or move it on to formulators.

    What that changes at the count

    • For a formulator. Issues are checked against batch records, so use can be tied to what was made.
    • For a bulk drug maker. Finished API is valued with its release status, since unreleased goods cannot be sold.
    • For a contract maker. The first question is whose stock it is, before anyone asks how much.
    Same material, different role. One drum can be a raw material at one business, a finished product at another and a client’s property at a third.

    In practice

    03 How API stock is controlled in practice

    ReceivedIssuedSamplesShould remain
    Line of the batch reconciliation Where it comes from Sample (kg)
    Received Goods receipt against the supplier’s certificate of analysis 120.0
    Issued to production The batch records of the products made 96.4
    Samples and retained quantity The quality control sampling record 1.6
    Should remain Compared with the weighed balance on the rack 22.0

    120.0 − 96.4 − 1.6 = 22.0 kg. Anything destroyed is deducted too. Sample figures for illustration only.

    From receipt to batch record

    1. Receive into a blocked status

      Against a purchase specification and the supplier’s certificate of analysis, booked as quarantined at once.

    2. Sample and test

      Against the specification. The supplier’s certificate supports the check; it does not replace it.

    3. Release by quality control

      Only released material can be issued, however urgent the production plan.

    4. Store with its batch identity

      In the set conditions, with the batch number staying with the material through every move.

    5. Issue and reconcile by batch

      Use is recorded on the batch record of the product made, and each API batch is reconciled to what is left.

    Worked example

    04 Where the value of one batch sits

    Sample figures for one batch.

    One batch of 60,000 tablets, broken into its three material inputs
    Input Quantity and rate Value (INR)
    API 42 kg at 78,000 per kg 32,76,000
    Excipients 1,850 kg at 240 per kg 4,44,000
    Packaging 60,000 units at 9 each 5,40,000
    Batch total Three inputs 42,60,000

    Checking effort follows value, not volume

    The API is just over 2 kg in every 100 kg of material in the batch, yet about three-quarters of its value. A counting error of one-twentieth on the excipients (92.5 kg) moves the batch value by 22,200; the same one-twentieth on the API (2.1 kg) moves it by 1,63,800.

    That is why the API is weighed on calibrated scales, reconciled batch by batch and kept under separate access, while excipients are checked more lightly. The smallest quantity in the table takes the most attention.

    Framework

    05 Active pharmaceutical ingredients under Indian rules

    Making an active ingredient is a licensed activity. Manufacture needs a licence from the state licensing authority, and the site must meet Schedule M good manufacturing practice under the Drugs and Cosmetics Rules, 1945. Schedule M also keeps incoming materials in quarantine until quality control has tested and released them, which is why release status is part of every API count.

    Verified

    Licence and good manufacturing practice

    A state manufacturing licence, with the site meeting Schedule M good manufacturing practice under the Drugs and Cosmetics Rules, 1945.

    Acts and rules on CDSCO
    Verified

    Quarantine until released

    Under Schedule M, incoming materials stay in quarantine until tested and released by quality control.

    Acts and rules on CDSCO
    Verified

    Revised Schedule M

    Revised by G.S.R. 922(E) of 28 December 2023; the extended compliance date for smaller manufacturers ran to 31 December 2025.

    CDSCO

    Watch out

    06 Common mistakes with API stock

    Quantity is the least of what has to be right.

    Counting without release status

    Material still awaiting a quality decision is shown as available.

    Record quarantined, released and rejected stock apart.

    Lots stored together unmarked

    The total is known but not the split between batches.

    Keep each batch labelled and counted on its own.

    Missing a passed retest date

    The material looks ordinary but cannot be used until retested.

    Check every lot’s retest date at the count.

    Ignoring how it was stored

    A recorded temperature breach can make the material unusable.

    Read the storage log before accepting the value.

    Reconciling use only in total

    Losses that a batch-by-batch check would show stay hidden.

    Reconcile each API batch to its batch records.

    Relying on the supplier certificate alone

    The specification may call for in-house testing as well.

    Test on receipt where the specification requires it.

    Question

    07 Active pharmaceutical ingredient FAQ

    How to make active pharmaceutical ingredient?

    An API is made in a manufacturing plant, usually by chemical synthesis or by a biological process such as fermentation, and is then purified and tested against its specification before quality control releases it. In India, manufacturing active ingredients needs a licence from the state licensing authority, and the site must meet Schedule M good manufacturing practice under the Drugs and Cosmetics Rules, 1945.

    CA Sundram Gupta

    Reviewed by CA Sundram Gupta · Chartered Accountant

    Patron Accounting LLP. Statements on the Drugs and Cosmetics Rules and Schedule M on this page signed off by CA Sundram Gupta: 23 October 2026

    Last reviewed: 23 October 2026 Applies to: pharmaceutical manufacturers, contract manufacturers and distributors holding active ingredients; the licensing points apply to manufacturers in India

    Sources: Drugs and Cosmetics Act, 1940 and Rules, 1945, Schedule M as revised by G.S.R. 922(E) of 28 December 2023 (CDSCO). General information, not professional advice; check the current position for your site before acting.

    Need help with active pharmaceutical ingredients? See our stock audit for pharmaceutical manufacturing service. A pharmaceutical stock audit counts API by batch and release status.

    Talk to an expert

    Tell us what you need and the right person calls you back.

    🇮🇳 +91

      By sending this form you agree to our privacy policy.